Rhythm Pharmaceuticals
RYTM
114 hedge funds and large institutions have $1.81B invested in Rhythm Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 42 increasing their positions, 27 reducing their positions, and 12 closing their positions.
117% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 12
56% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 27
25% more capital invested
Capital invested by funds: $1.45B → $1.81B (+$365M)
21% more call options, than puts
Call options by funds: $15.5M | Put options by funds: $12.9M
13% more funds holding
Funds holding: 101 → 114 (+13)
3.57% more ownership
Funds ownership: 106.77% → 110.34% (+3.6%)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$13.8M |
| 2 |
Alkeon Capital Management
New York
|
+$13.7M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$12.3M |
| 4 |
Goldman Sachs
New York
|
+$10.9M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$9.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$15.4M |
| 2 |
Janus Henderson Group
London,
|
-$8.25M |
| 3 |
Walleye Capital
New York
|
-$4.69M |
| 4 |
Primecap Management
Pasadena,
California
|
-$2.97M |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$2.44M |
RYTM Hedge Fund Activity: Q4 2022 in Review
114 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Rhythm Pharmaceuticals (RYTM) for Q4 2022, worth a combined $1.81B — up 25% from $1.45B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new RYTM positions and 12 closed out — a net gain of 14 holders — while 42 added to existing stakes and 27 trimmed.
The largest buyer was Polar Capital Holdings, adding an estimated $13.8M. The largest seller was Fidelity Investments, cutting an estimated $15.4M.
- 114 institutional investors held Rhythm Pharmaceuticals (RYTM) as of Q4 2022, up from 101 in Q3 2022.
- Funds reported $1.81B of Rhythm Pharmaceuticals stock for Q4 2022, up 25% quarter-over-quarter.
- 26 funds opened new Rhythm Pharmaceuticals positions in Q4 2022 and 12 closed out, a net change of +14 holders.
- The largest Rhythm Pharmaceuticals buyer in Q4 2022 was Polar Capital Holdings, an estimated $13.8M added.
- The largest Rhythm Pharmaceuticals seller in Q4 2022 was Fidelity Investments, an estimated $15.4M sold.
Based on aggregated 13F filings for Q4 2022.